Bloomberg -- Eli Lilly & Co. reported fourth- quarter profit of $915.4 million on higher sales of its top- seller, the antipsychotic Zyprexa, and cancer therapy Alimta.
Bloomberg -- Eli Lilly & Co. reported fourth- quarter profit of $915.4 million on higher sales of its top- seller, the antipsychotic Zyprexa, and cancer therapy Alimta.